Veledimex (S enantiomer)
Modify Date: 2024-01-05 09:18:35
Veledimex (S enantiomer) structure
|
Common Name | Veledimex (S enantiomer) | ||
|---|---|---|---|---|
| CAS Number | 1093131-03-3 | Molecular Weight | 438.6 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C27H38N2O3 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Veledimex (S enantiomer)Veledimex S enantiomer is the S enantiomer of veledimex. Veledimex is an oral activator ligand for a proprietary gene therapy promoter system, and a moderate inhibitor of and substrate for CYP3A4/5. |
| Name | Veledimex (S enantiomer) |
|---|
| Description | Veledimex S enantiomer is the S enantiomer of veledimex. Veledimex is an oral activator ligand for a proprietary gene therapy promoter system, and a moderate inhibitor of and substrate for CYP3A4/5. |
|---|---|
| Related Catalog | |
| In Vivo | Veledimex generally has moderate to low oral bioavailability after a single oral administration in mice and monkeys (∼56% in mice and up to 17.4% in cynomolgus monkeys) with mostly low plasma clearance (1399 and 1170 mL/h per kilogram in mice and monkeys, respectively), high volume of distribution (20271 and 9180 mL/h per kilogram in mice and monkeys, respectively), and long terminal half-lives (∼10 hours in mice and ∼30 hours in monkeys) after intravenous administration[1]. Ad-RTS-mIL-12 + veledimex have demonstrated a dose-related increase in tumor IL-12 mRNA and IL-12 protein expression. Discontinuation of veledimex resulted in a return to baseline IL-12 mRNA and protein expression in numerous syngeneic mouse tumor models. Veledimex crosses the blood-brain-barrier in both naive and orthotopic GL-261 mice with increased brain tissue level of ∼6 fold observed in tumor bearing vs. normal mice. Ad-RTS-mIL-12 + veledimex demonstrate a dose-related increase in survival without significant adverse events[2]. |
| References |
| Molecular Formula | C27H38N2O3 |
|---|---|
| Molecular Weight | 438.6 |
| Storage condition | 2-8℃ |